PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS).
PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.
Company Details
- Employees
- 40
- Founded
- -
- Address
- Ul. Botaniczna 20, Gdańsk,pomorskie 80-298,poland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://poltreg.com/
- HQ
- Gdańsk, Pomorskie
Poltreg S.a. Questions
Poltreg S.A.'s website is https://poltreg.com/
Poltreg S.A.'s LinkedIn profile is https://pl.linkedin.com/company/poltreg-s-a
Poltreg S.A. has
40 employees.
View email and phone details for 40
employees at Poltreg S.A..
Poltreg S.A.'s industry is
Biotechnology Research
Poltreg S.A.'s top competitors are
Jjp Biologics,
Polpharma Biologics,
Bioceltix,
Molecure,
Celon Pharma S.a.,
Adamed Pharma,
Captor Therapeutics Sa,
Antion Biosciences Sa,
Ryvu Therapeutics,
Pure Biologics.
Poltreg S.A.'s categories are Biotechnology Research
Poltreg S.A.'s founding year is 2015
